The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...

Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from ...